| 引用本文: | 周仕海,罗平.生物制剂治疗原发性干燥综合征的研究进展[J].中国现代应用药学,2022,39(17):2293-2300. |
| ZHOU Shihai,LUO Ping.Research Progress on Biologics in the Treatment of Primary Sjögren's Syndrome[J].Chin J Mod Appl Pharm(中国现代应用药学),2022,39(17):2293-2300. |
|
| 摘要: |
| 原发性干燥综合征(primary Sjögren’s syndrome，pSS)是一种唾液腺和泪腺功能丧失的慢性自身免疫性疾病。pSS传统的治疗主要包括局部对症治疗和免疫抑制剂等，但疗效往往不佳且不良反应发生率较高。近年来随着pSS发病机制研究的不断深入，生物靶向疗法已成为一种治疗pSS的新选择。本文就近年来应用于pSS治疗的生物靶向制剂作综述，着重介绍不同类型生物制剂的作用靶点、分子生物学机制及临床疗效，旨在为pSS患者的治疗提供参考。 |
| 关键词: 原发性干燥综合征 生物制剂 B细胞受体 T细胞受体 细胞因子 |
| DOI：10.13748/j.cnki.issn1007-7693.2022.17.021 |
| 分类号:R966 |
| 基金项目: |
|
| Research Progress on Biologics in the Treatment of Primary Sjögren's Syndrome |
|
ZHOU Shihai1,2, LUO Ping1
|
|
1.Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410008, China;2.Department of Pharmacy, Guihang Guiyang Hospital, Guiyang 550001, China
|
| Abstract: |
| Primary Sjögren's syndrome(pSS) is a chronic autoimmune disease characterized by loss of salivary and lacrimal gland function. Traditional therapies including local symptomatic treatment, therapies based on immunosuppressant and so on, which are not satisfactory and also accompanied by high incidence of adverse reactions. In recent years, with the progress in understanding the pathogenesis of pSS, targeted biotherapy has emerged as a new option for pSS therapy. This review summarized the bio-targeted agents against pSS in recent years, focused on the targets, molecular biological mechanisms and clinical efficacy of different types of bio-targeted agents, in order to provide reference for the clinical treatment of pSS. |
| Key words: primary Sjögren's syndrome biologics B cell receptor T cell receptor cytokines |
